病例报告：在对替雷利珠单抗维妥昔单抗耐药的融合阳性肺腺癌中使用卡马替尼进行挽救治疗。
Case report: Salvage capmatinib therapy in fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin.
作者信息
Lin Chien-Yu, Wei Sheng-Huan, Chen Yi-Lin, Lee Chung-Ta, Wu Shang-Yin, Ho Chung-Liang, Pavlick Dean C, Su Po-Lan, Lin Chien-Chung
机构信息
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
出版信息
Front Oncol. 2022 Aug 11;12:919123. doi: 10.3389/fonc.2022.919123. eCollection 2022.
Telisotuzumab vedotin is a -targeting antibody-drug conjugate that has demonstrated a good treatment response in patients with wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been standardized. Here, we present a case of a 56-year-old woman diagnosed with fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin.
替雷利珠单抗维泊妥珠单抗是一种靶向MET的抗体药物偶联物，已在野生型MET过表达的非鳞状非小细胞肺癌患者中显示出良好的治疗反应。然而，据报道患者会对该药物产生耐药性，且后续治疗尚未标准化。在此，我们报告一例56岁女性患者，诊断为融合阳性非小细胞肺癌，在对替雷利珠单抗维泊妥珠单抗产生获得性耐药后，对卡马替尼有持久反应。
Zotero 插件